Skip to main content
COVID-19

Persistence of Beta- Blocker Treatment After a Heart Attack (PBH)

HEDIS Measure

Persistence of Beta- Blocker Treatment After a Heart Attack (PBH)

Line of business: Commercial Medicaid Medicare

Data Collection Method: Administrative

Measure Description

The percentage of members 18 years of age and older during the measurement year who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of AMI and who received persistent beta-blocker treatment for six months after discharge.

Numerator Compliance

At least 135 days of treatment with beta-blockers during the 180-day measurement interval. This allows gaps in medication treatment of up to a total of 45 days during the 180-day measurement interval.

Beta-Blocker Medications

Description Prescriptions
Noncardioselective beta-blockers Carvedilol, Labetalol, Nadolol, Pindolol, Propranolol, Timolol, Sotalol
Cardioselective beta-blockers Acebutolol, Atenolol, Betaxolol, Bisoprolol
Antihypertensive combinations Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide